04/29/21
EU Vaccine Injury Reporting System Shows More Than 330,000 Adverse Events Following COVID Vaccines
Health Impact News compiled the latest data on reports of COVID vaccine injuries and deaths in EU countries following vaccination with all four COVID vaccines approved in the EU for emergency use.
Every week The Defender publishes the latest data from the Vaccine Adverse Events Reporting System (VAERS) on injuries and deaths reported after people received one of the three COVID vaccines that have received Emergency Use Authorization in the U.S.
VAERS, which operates under the Centers for Disease Control and Prevention, is the primary government-funded system for reporting adverse vaccine reactions in the U.S. In the EU, suspected drug reactions are reported to EudraVigilance, which also tracks reports of injuries and deaths following the experimental COVID vaccines.
Health Impact News compiled the latest EudraVigilance data on reports of COVID vaccine-related injuries and deaths and found — as of April 17 — 7,766 reports of deaths and 330,218 reports of injuries following injections of the four COVID vaccines approved for emergency use in the EU: Moderna, Pfizer, AstraZeneca and Johnson & Johnson, marketed under the Janssen brand.
The Health Impact News report broke down the data by vaccine, type of injury and country.
According to the report, injury and death report totals for each vaccine were:
Pfizer-BioNTech: 4,293 deaths and 144,607 injuries
Moderna: 2,094 deaths and 15,979 injuries
AstraZeneca: 1,360 deaths and 169,386 injuries
Johnson & Johnson (Janssen): 19 deaths and 246 injuries
Cardiac and blood/lymphatic disorders were among the most commonly reported injuries.
According to its website, EudraVigilance was launched by the European Medicines Agency in 2012. Reports of suspected adverse events are submitted electronically to EudraVigilance by national medicines regulatory authorities and by pharmaceutical companies that hold marketing authorizations (licenses) for the medicines.
::::::::::::::::::::::::::::::
